Drug Trial Radar · NCT06194799
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
752
Planned (sponsor's estimate)
Start
Apr 23, 2024
Primary completion
Apr 2029
Study completion May 2029
Sponsor
- Lead sponsor
- ACADIA Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 95 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Conditions
- Alzheimer's Disease Psychosis
Interventions
ACP-204Drug
ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse eventsTime frame: 52 Weeks
Locations
78 sites in 12 countries. Site status is shown where the registry gives one.
Clinical Endpoints LLC
Scottsdale, Arizona
ATP Clinical Research
Costa Mesa, California
Neuro-Pain Medical Center
Fresno, California
National Institute Of Clinical Research
Garden Grove, California
Humanity Clinical Research, Corp
Aventura, Florida
First Excellent Research
Doral, Florida
New Life Medical Research Center
Hialeah, Florida
Reliable Clinical Research LLC
Hialeah, Florida
Homestead Associates in Research Inc.
Miami, Florida
Premier Clinical Research Institute Inc
Miami, Florida
Advanced Clinical Research
Miami, Florida
Verus Clinical Research
Miami, Florida
Quantum Clinical Trials
Miami, Florida
Future Care Solution, LLC
Miami, Florida
MediClear Medical & Research Center, Inc.
Miami, Florida
ABBA Medical Research LLC
Miami, Florida
New Med Research
Miami Gardens, Florida
Floridian Neuroscience Institute
Miami Lakes, Florida
Abington Neurological Associates
Abington, Pennsylvania
Horizon Clinical Research Group
Cypress, Texas
Uni Texas Health Science Center
Houston, Texas
Clinical Trial Network LLC
Houston, Texas
Kaleidoscope Clinical Research
Houston, Texas
Hospital Universitario de Brasilia
Brasília, Brazil
CECPAR Centro de Estudos Clinicos do Parana
Curitiba, Brazil
TrialTech Tecnologia com Pesquisas em Medicamentos
Curitiba, Brazil
Inst de Neurologia de Curitiba Hospital Ecoville
Curitiba, Brazil
Instituto Mederi de Pesquisa e Saude
Passo Fundo, Brazil
Ruschel Medicina e Pesquisa Clínica
Rio de Janeiro, Brazil
Facili - Centro Integrado de Psiquiatria
São Bernardo do Campo, Brazil
BR Trials-Ensaios Clinicos e Consultoria
São Paulo, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
ET Dr. Ivo Natsov-AIPSMC in Psychiatry
Cherven Bryag, Bulgaria
DCC Higia
Pazardzhik, Bulgaria
Medical center Medconsult Pleven OOD
Pleven, Bulgaria
Mental Health Centre-Prof. N Shipkovenski EOOD
Sofia, Bulgaria
DCC St. Vrach and St. St. Kuzma and Damian OOD
Sofia, Bulgaria
UMHAT Alexandrovska EAD
Sofia, Bulgaria
Psicomed Estudios Medicos
Antofagasta, Chile
Biomedica Research Group
Santiago, Chile
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.